propofol has been researched along with Neuroleptic Malignant Syndrome in 8 studies
Propofol: An intravenous anesthetic agent which has the advantage of a very rapid onset after infusion or bolus injection plus a very short recovery period of a couple of minutes. (From Smith and Reynard, Textbook of Pharmacology, 1992, 1st ed, p206). Propofol has been used as ANTICONVULSANTS and ANTIEMETICS.
propofol : A phenol resulting from the formal substitution of the hydrogen at the 2 position of 1,3-diisopropylbenzene by a hydroxy group.
Neuroleptic Malignant Syndrome: A potentially fatal syndrome associated primarily with the use of neuroleptic agents (see ANTIPSYCHOTIC AGENTS) which are in turn associated with dopaminergic receptor blockade (see RECEPTORS, DOPAMINE) in the BASAL GANGLIA and HYPOTHALAMUS, and sympathetic dysregulation. Clinical features include diffuse MUSCLE RIGIDITY; TREMOR; high FEVER; diaphoresis; labile blood pressure; cognitive dysfunction; and autonomic disturbances. Serum CPK level elevation and a leukocytosis may also be present. (From Adams et al., Principles of Neurology, 6th ed, p1199; Psychiatr Serv 1998 Sep;49(9):1163-72)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Malignant catatonia (MC) is a movement disorder syndrome characterized by immobility, rigidity, and consciousness disorders that develops in association with mental and physical diseases." | 5.62 | Successful diagnosis and treatment of pulmonary aspergillosis-related malignant catatonia using propofol and quetiapine: A case report. ( Aisaka, W; Narimatsu, E; Nomura, K; Okamoto, H; Sakawaki, E; Sakawaki, S; Takeyama, Y; Uemura, S; Yamaoka, A, 2021) |
| "Malignant catatonia (MC) is a movement disorder syndrome characterized by immobility, rigidity, and consciousness disorders that develops in association with mental and physical diseases." | 1.62 | Successful diagnosis and treatment of pulmonary aspergillosis-related malignant catatonia using propofol and quetiapine: A case report. ( Aisaka, W; Narimatsu, E; Nomura, K; Okamoto, H; Sakawaki, E; Sakawaki, S; Takeyama, Y; Uemura, S; Yamaoka, A, 2021) |
| " NMS is associated with administration of antipsychotic medications, anti-emetic medications, and changes in the dosage of anti-parkinsonian drugs." | 1.38 | Anesthetic management of a pediatric patient with neuroleptic malignant syndrome. ( Bhalla, T; Maxey, D; Sawardekar, A; Tobias, JD, 2012) |
| "A 66-year-old man received medical treatment of depression for several years." | 1.35 | [Anesthetic management for electroconvulsive therapy using target-controlled infusion of propofol]. ( Imashuku, Y; Ishikawa, Y; Kitagawa, H; Kojima, A; Kuzukawa, A; Nosaka, S, 2008) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (25.00) | 18.2507 |
| 2000's | 1 (12.50) | 29.6817 |
| 2010's | 2 (25.00) | 24.3611 |
| 2020's | 3 (37.50) | 2.80 |
| Authors | Studies |
|---|---|
| Soh, M | 1 |
| Hifumi, T | 1 |
| Isokawa, S | 1 |
| Shimizu, M | 1 |
| Otani, N | 1 |
| Ishimatsu, S | 1 |
| Sohn, JT | 1 |
| Nomura, K | 1 |
| Sakawaki, S | 1 |
| Sakawaki, E | 1 |
| Yamaoka, A | 1 |
| Aisaka, W | 1 |
| Okamoto, H | 1 |
| Takeyama, Y | 1 |
| Uemura, S | 1 |
| Narimatsu, E | 1 |
| Casas Reza, P | 1 |
| Gestal Vázquez, M | 1 |
| Outeiro Rosato, Á | 1 |
| López Álvarez, S | 1 |
| Diéguez García, P | 1 |
| Imashuku, Y | 1 |
| Kitagawa, H | 1 |
| Kojima, A | 1 |
| Ishikawa, Y | 1 |
| Kuzukawa, A | 1 |
| Nosaka, S | 1 |
| Bhalla, T | 1 |
| Maxey, D | 1 |
| Sawardekar, A | 1 |
| Tobias, JD | 1 |
| Sakamoto, A | 1 |
| Hoshino, T | 1 |
| Suzuki, H | 1 |
| Kimura, M | 1 |
| Ogawa, R | 1 |
| Rupreht, J | 1 |
| Verkaaik, AP | 1 |
| Erdmann, W | 1 |
8 other studies available for propofol and Neuroleptic Malignant Syndrome
| Article | Year |
|---|---|
The authors' response: Propofol in COVID 19: From basic science to clinical impact.
Topics: COVID-19; Humans; Hypnotics and Sedatives; Neuroleptic Malignant Syndrome; Propofol; SARS-CoV-2 | 2021 |
Propofol and sedation in patients with coronavirus disease.
Topics: Conscious Sedation; Coronavirus; COVID-19; Humans; Hypnotics and Sedatives; Neuroleptic Malignant Sy | 2021 |
Successful diagnosis and treatment of pulmonary aspergillosis-related malignant catatonia using propofol and quetiapine: A case report.
Topics: Catatonia; Diagnosis, Differential; Female; Humans; Hypnotics and Sedatives; Middle Aged; Neurolepti | 2021 |
Rocuronium-sugammadex for electroconvulsive therapy management in neuroleptic malignant syndrome: A case report.
Topics: Androstanols; Anesthetics, Intravenous; Antipsychotic Agents; Clozapine; Electroconvulsive Therapy; | 2017 |
[Anesthetic management for electroconvulsive therapy using target-controlled infusion of propofol].
Topics: Aged; Anesthetics, Intravenous; Depression; Electroconvulsive Therapy; Humans; Infusions, Intravenou | 2008 |
Anesthetic management of a pediatric patient with neuroleptic malignant syndrome.
Topics: Adolescent; Anesthesia, General; Anesthetics; Anesthetics, Intravenous; Antipsychotic Agents; Bipola | 2012 |
Repeated propofol anesthesia for a patient with a history of neuroleptic malignant syndrome.
Topics: Amoxapine; Anesthesia, Intravenous; Anesthetics, Intravenous; Antidepressive Agents, Second-Generati | 1999 |
Propofol safely used in a neuroleptic malignant syndrome patient.
Topics: Anesthesia, Intravenous; Colectomy; Female; Humans; Middle Aged; Neuroleptic Malignant Syndrome; Pro | 1991 |